Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma

European Urology, Supplements

Volumn 7, Issue 9, 2008, Pages 593-600

  Roigas, Jan ^a  

^a VIVANTES KLINIKUM AM URBAN   (Germany)

Author keywords

Adverse event; Renal cell carcinoma; Sunitinib; Therapy management; Tyrosine kinase inhibitor

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CORTICOSTEROID; CYANOCOBALAMIN; IRON; KETOCONAZOLE; LOPERAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; RETINOL; RIFAMPICIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADVANCED CANCER; ANEMIA; ANOREXIA; ASTHENIA; BLOOD TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMORBIDITY; DIARRHEA; DIET THERAPY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; FATIGUE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; LEUKOPENIA; LIFESTYLE MODIFICATION; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PATIENT CARE; PATIENT EDUCATION; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; RISK FACTOR; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 49149104996     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2008.06.004     Document Type: Review

References (14)

1. Houk B., Bello C.L., Michaelson M.D., et al. A population pharmacokinetic/pharmacodynamic (PK/PD) analysis of exposure-response for sunitinib in metastatic renal cell carcinoma (mRCC) [abstract]. Eur J Cancer Suppl 5 (2007) 299
2. Sutent, summary of product characteristics. New York, NY: Pfizer Inc; 2008.
3. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
4. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
5. Motzer R.J., Michaelson M.D., Rosenberg J., et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 178 (2007) 1883-1887
6. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
7. Gore M., Szczylik C., Porta C., et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of safety and efficacy in an expanded access trial with subpopulation analysis [abstract]. Eur J Cancer Suppl 5 (2007) 299
8. Bellmunt J. Sunitinib in advanced renal cell carcinoma: clinical evidence. Eur Urol Suppl 7 (2008) 585-592
9. Negrier S., and Ravaud A. Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management. Eur J Cancer Suppl 5 (2007) 12-19
10. Robert C., Soria J.C., Spatz A., et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6 (2005) 491-500
11. Rini B.I., Tamaskar I., Shaheen P., et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99 (2007) 81-83
12. Schöffski P., Wolter P., Himpe D.R., et al. Sunitinib-related thyroid dysfunction: a single-center retrospective and prospective evaluation. J Clin Oncol 24 (2006) 3092
13. Raut C., Morgan J.A., Quigley M.T., et al. Postoperative experience in patients with metastatic GIST are similar in patients while on sunitinib or imatinib. Eur J Cancer Suppl 5 (2007) 409
14. Thibault F., Billemont B., and Rixe O. Perioperative use and surgical complications of sunitinib in metastatic renal cell carcinoma. Eur Urol Suppl 7 (2008) 306